Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Deep Vein Thrombosis: early-phase trial registry
5 of 25 indexed Deep Vein Thrombosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #652 of 28,707 conditions by registered trial count.
25 US clinical trials · 5 currently recruiting · #652 of 28,707 conditions by registered trial count
Deep Vein Thrombosis: 25 US clinical trials tracked, 5 recruiting.
Deep Vein Thrombosis is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Brigham and Women's Hospital, running 3 of these trials.
Enrollment posture brief
Registry condition deep-vein-thrombosis
OPEN 5 | RECR 20% | LATE 3 | EARLY 5 | RANK #652 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Deep Vein Thrombosis lists 5 open slots (20% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Deep Vein Thrombosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Deep Vein Thrombosis is recruiting below its size-band peers.
5 of 25 indexed trials (20%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Deep Vein Thrombosis trials is spread across many organizations.
Brigham and Women's Hospital accounts for 3 of 25 trials (12%). 21 distinct sponsors appear on at least one study for this condition label.
-
Typical Deep Vein Thrombosis enrolment sits around 229 participants.
Median target enrolment is 229 among the 25 trials that report a genuine target (sentinel values excluded). 8 of those (32%) plan for fewer than 100 participants.
-
Deep Vein Thrombosis research is mostly interventional.
20 interventional and 5 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
25 total, page 1 of 1
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
Scott C. Woller, MD
NCT06232551
Non-invasive Venous Air Plethysmography Assessment of Venous Hemodynamics in Patients Suspected Deep Venous Obstruction Used in Conjunction With Intermittent Pneumatic Compression.
Mayo Clinic
NCT06519435
Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Detection
ThinkSono
NCT06652568
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
Medical University of South Carolina
NCT06451003
Apixaban in Thrombocytopenia
Rushad Patell
NCT06886516
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
Penumbra
NCT05003843
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Washington University School of Medicine
NCT03250247
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
Inova Health Care Services
NCT07250763
Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events
Vanderbilt University Medical Center
NCT04574895
Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events
Thrombosis Research Institute
NCT02155491
Epidemiology of Venous Thromboembolism
Brigham and Women's Hospital
NCT00456196
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Washington University School of Medicine
NCT00790335
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
Bristol-Myers Squibb
NCT00252005
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
McMaster University
NCT00720915
Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information
Brigham and Women's Hospital
NCT00401414
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United
NCT02585713
Evaluation of the Accuracy and Precision of the INRatio® Prothrombin Time (PT) Monitoring System With New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity
Abbott RDx Cardiometabolic
NCT01037270
A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics
University of Puerto Ri
NCT02345356
Multimodal DVT Protocol in Tourniquet-less Total Knee Arthroplasty
TriHealth
NCT02102828
Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
University of Utah
NCT03339349
Non-Interruptive Alerts for Improving Use of Clinical Decision Rules
University of Utah
NCT04702308
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
Daiichi Sankyo
NCT02303431
Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism
Brigham and Women's Hospital
NCT00413374
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
University of Vermont
NCT01524653
Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome (PTS)
University of North Carolina, Chapel Hill
NCT00858130
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Deep Vein Thrombosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Deep Vein Thrombosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Deep Vein Thrombosis page
25 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Deep Vein Thrombosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Brigham and Women's Hospital sponsors the most Deep Vein Thrombosis trials on record, review their full trial history before evaluating a specific study. See Brigham and Women's Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Deep Vein Thrombosis condition card totals 25 registered trials; most-linked intervention Apixaban; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.